$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000095017024096148 Filed on August 13, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue		$526.0K	$2.088M
YoY Change		-74.81%	-16.65%
Cost Of Revenue			$1.840M
YoY Change			16.53%
Gross Profit			$248.0K
YoY Change			-73.22%
Gross Profit Margin			11.88%
Selling, General & Admin		$5.514M	$5.984M
YoY Change		-7.85%	167.62%
% of Gross Profit			2412.9%
Research & Development	$12.03M	$9.275M	$5.653M
YoY Change	110.24%	64.07%	610.18%
% of Gross Profit			2279.44%
Depreciation & Amortization		$572.0K	$260.0K
YoY Change		120.0%	246.67%
% of Gross Profit			104.84%
Operating Expenses	$19.00M	$14.79M	$11.62M
YoY Change	68.59%	27.25%	283.31%
Operating Profit	-$18.63M	-$14.26M	-$11.37M
YoY Change	76.89%	25.4%	440.08%
Interest Expense		$3.049M	$28.00K
YoY Change		10789.29%	0.0%
% of Operating Profit
Other Income/Expense, Net	$3.512M	$3.049M	$268.0K
YoY Change	1873.03%	1037.69%	857.14%
Pretax Income	-$15.12M	-$11.21M	-$11.11M
YoY Change	46.02%	0.97%	434.46%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$15.12M	-$11.70M	-$11.11M
YoY Change	46.02%	5.38%	434.46%
Net Earnings / Revenue		-2225.1%	-531.9%
Basic Earnings Per Share	-$0.21	-$0.18	-$0.04
Diluted Earnings Per Share	-$0.21	-$0.18	-$0.04
COMMON SHARES
Basic Shares Outstanding	67.43M	622.6M	280.1M
Diluted Shares Outstanding	70.63M	66.65M	28.00M

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$292.9M	$28.30M
YoY Change		934.87%	-49.36%
Cash & Equivalents	$226.4M	$252.0M	$28.32M
Short-Term Investments		$40.87M
Other Short-Term Assets		$1.226M	$1.400M
YoY Change		-12.43%	5085.19%
Inventory			$1.094M
Prepaid Expenses
Receivables	$217.0K	$142.0K	$1.113M
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$270.2M	$294.2M	$31.95M
YoY Change	1145.72%	820.81%	-46.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$43.79M	$14.75M	$7.043M
YoY Change	524.53%	109.39%	256.43%
Goodwill	$24.10M	$24.06M	$27.32M
YoY Change	-11.78%	-11.92%
Intangibles			$50.00M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$694.0K	$672.0K	$573.0K
YoY Change	25.95%	17.28%	435.51%
Total Long-Term Assets	$121.0M	$91.68M	$88.19M
YoY Change	36.19%	3.96%	1625.85%
TOTAL ASSETS
Total Short-Term Assets	$270.2M	$294.2M	$31.95M
Total Long-Term Assets	$121.0M	$91.68M	$88.19M
Total Assets	$391.2M	$385.9M	$120.1M
YoY Change	253.93%	221.21%	86.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$6.127M	$4.900M
YoY Change		25.04%	407.25%
Accrued Expenses		$3.029M	$3.600M
YoY Change		-15.86%	176.92%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$54.00K	$100.0K
YoY Change		-46.0%
Total Short-Term Liabilities	$28.14M	$10.61M	$8.589M
YoY Change	246.8%	23.53%	279.04%
LONG-TERM LIABILITIES
Long-Term Debt		$1.651M	$1.700M
YoY Change		-2.88%
Other Long-Term Liabilities	$33.00K	$19.00K	$1.200M
YoY Change	-98.3%	-98.42%	33.93%
Total Long-Term Liabilities	$33.00K	$19.00K	$2.900M
YoY Change	-99.09%	-99.34%	223.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.14M	$10.61M	$8.589M
Total Long-Term Liabilities	$33.00K	$19.00K	$2.900M
Total Liabilities	$62.68M	$44.92M	$11.49M
YoY Change	433.55%	290.9%	263.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$191.6M	-$176.4M	-$117.4M
YoY Change	49.92%	50.27%	19.08%
Common Stock	$520.0M	$517.4M	$226.1M
YoY Change	129.55%	128.89%	41.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$328.5M	$341.0M	$108.7M
YoY Change
Total Liabilities & Shareholders Equity	$391.2M	$385.9M	$120.1M
YoY Change	253.93%	221.21%	86.45%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$15.12M	-$11.70M	-$11.11M
YoY Change	46.02%	5.38%	434.46%
Depreciation, Depletion And Amortization		$572.0K	$260.0K
YoY Change		120.0%	246.67%
Cash From Operating Activities		-$8.902M	-$8.080M
YoY Change		10.17%	179.49%
INVESTING ACTIVITIES
Capital Expenditures		$1.015M	$570.0K
YoY Change		78.07%	-563.41%
Acquisitions
YoY Change
Other Investing Activities		-$2.280M	$0.00
YoY Change
Cash From Investing Activities		-$3.295M	-$570.0K
YoY Change		478.07%	363.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		122.1M	510.0K
YoY Change		23838.04%
NET CHANGE
Cash From Operating Activities		-8.902M	-8.080M
Cash From Investing Activities		-3.295M	-570.0K
Cash From Financing Activities		122.1M	510.0K
Net Change In Cash		109.9M	-8.140M
YoY Change		-1449.96%	170.07%
FREE CASH FLOW
Cash From Operating Activities		-$8.902M	-$8.080M
Capital Expenditures		$1.015M	$570.0K
Free Cash Flow		-$9.917M	-$8.650M
YoY Change		14.65%	212.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	656000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-12284000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	229891000
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	128000
CY2024Q2	catx	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	123000
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	719000
CY2024Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-1000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-11704000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	340997000
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	292900000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176400000
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	292900000
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reclassifications</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the discontinued operations discussed above, during the first quarter of 2024, the Company made certain reclassifications to prior period amounts in the condensed consolidated financial statements and accompanying notes to conform to the current period presentation. The reclassification of these items had no impact on net loss, financial position or cash flows in the current or prior periods. Specifically, accrued payroll and related taxes and accrued vacation were combined to create accrued personnel, and accrued protocol expense and accrued waste disposal were included in accounts payable and accrued expenses, all of which are presented on the condensed consolidated balance sheets and condensed consolidated statement of cash flows.</span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7350000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5090000
CY2023Q4	catx	Maximum Amount Of Securities Offer And Sale MaximumAmountOfSecuritiesOfferAndSale	200000000
CY2024Q2	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
CY2023Q2	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16332000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6245000
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1585000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	669000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14747000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5576000
CY2024Q2	us-gaap	Goodwill Goodwill	24100000
CY2023Q4	us-gaap	Goodwill Goodwill	24100000
CY2024Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000
CY2024Q2	catx	Indefinitelived Intangible Assets Accumulated Amortization IndefinitelivedIntangibleAssetsAccumulatedAmortization	0
CY2024Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000
CY2023Q4	catx	Indefinitelived Intangible Assets Accumulated Amortization IndefinitelivedIntangibleAssetsAccumulatedAmortization	0
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2024Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2024Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2024Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2024Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33407
	dei	Entity Registrant Name EntityRegistrantName	PERSPECTIVE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	41-1458152
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2401 Elliott Avenue, Suite 320
	dei	Entity Address City Or Town EntityAddressCityOrTown	Seattle
	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98121
	dei	City Area Code CityAreaCode	206
	dei	Local Phone Number LocalPhoneNumber	676-0900
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	CATX
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67427667
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	252004000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9238000
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	40865000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	606000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	650000
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	142000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1165000
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1226000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1133000
CY2024Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5301000
CY2024Q2	us-gaap	Assets Current AssetsCurrent	294237000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	16837000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14747000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5576000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2019000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	747000
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000
CY2024Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000
CY2024Q2	us-gaap	Goodwill Goodwill	24062000
CY2023Q4	us-gaap	Goodwill Goodwill	24062000
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	672000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	487000
CY2024Q2	us-gaap	Assets Assets	385919000
CY2023Q4	us-gaap	Assets Assets	97891000
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6127000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6909000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	720000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46000
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2309000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3588000
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	54000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	49000
CY2024Q2	us-gaap	Deferred Income Current DeferredIncomeCurrent	1400000
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	0
CY2024Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	5072000
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10610000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15664000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1450000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	780000
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1651000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1676000
CY2024Q2	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	26600000
CY2023Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	0
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4592000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4592000
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	19000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2024Q2	us-gaap	Liabilities Liabilities	44922000
CY2023Q4	us-gaap	Liabilities Liabilities	22712000
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67425167
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67425167
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28180985
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28180985
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	67000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	28000
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	517358000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	227591000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176428000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152440000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	340997000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	75179000
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	385919000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97891000
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
CY2024Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	526000
CY2023Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	588000
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	851000
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	821000
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9275000
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5370000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16727000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8679000
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5514000
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4987000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11392000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11650000
CY2024Q2	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	0
CY2023Q2	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	15000
	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	0
	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	15000
CY2024Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
CY2023Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-22000
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	14789000
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	10342000
	us-gaap	Operating Expenses OperatingExpenses	28119000
	us-gaap	Operating Expenses OperatingExpenses	20336000
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14263000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9754000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27268000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19515000
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3076000
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	294000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4287000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	668000
CY2024Q2	catx	Interest And Other Expense InterestAndOtherExpense	23000
CY2023Q2	catx	Interest And Other Expense InterestAndOtherExpense	26000
	catx	Interest And Other Expense InterestAndOtherExpense	52000
	catx	Interest And Other Expense InterestAndOtherExpense	44000
CY2024Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4000
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3049000
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	268000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4229000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	624000
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11214000
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9486000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23039000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18891000
CY2024Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-429000
CY2023Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1620000
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-890000
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-3086000
CY2024Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-61000
CY2023Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-59000
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0
CY2024Q2	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-11704000
CY2023Q2	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-11106000
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-23988000
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-21977000
CY2024Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2023Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10500000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-11704000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11106000
	us-gaap	Net Income Loss NetIncomeLoss	-23988000
	us-gaap	Net Income Loss NetIncomeLoss	-11477000
CY2024Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2024Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.17
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.34
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.34
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.4
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.4
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.33
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.33
CY2024Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.01
CY2024Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.01
CY2023Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.06
CY2023Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.06
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.01
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.01
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.12
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.12
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.4
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.4
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66648000
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66648000
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27999000
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27999000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58079000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58079000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25443000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25443000
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
	us-gaap	Net Income Loss NetIncomeLoss	-23988000
	us-gaap	Net Income Loss NetIncomeLoss	-11477000
	catx	Noncash Expense Lease NoncashExpenseLease	71000
	catx	Noncash Expense Lease NoncashExpenseLease	-14000
	us-gaap	Depreciation Depreciation	916000
	us-gaap	Depreciation Depreciation	425000
	us-gaap	Inventory Write Down InventoryWriteDown	0
	us-gaap	Inventory Write Down InventoryWriteDown	298000
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	12000
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	20000
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	17000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	360000
	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	0
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-44000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	0
	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	15000
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-59000
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0
	us-gaap	Share Based Compensation ShareBasedCompensation	1375000
	us-gaap	Share Based Compensation ShareBasedCompensation	2567000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10500000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1023000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-250000
	catx	Increase Decrease In Inventory Related To Discontinued Operations IncreaseDecreaseInInventoryRelatedToDiscontinuedOperations	-11000
	catx	Increase Decrease In Inventory Related To Discontinued Operations IncreaseDecreaseInInventoryRelatedToDiscontinuedOperations	-144000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	93000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	445000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-763000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	442000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	28000000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1279000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	471000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4946000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17795000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10087000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	756000
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	18000
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	38225000
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	22764000
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	78730000
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	2699000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50592000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24689000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	20000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	35000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	123000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	254000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	532000
	catx	Proceeds From Issuance Of Common Stock And Prefunded Warrants Net ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNet	288055000
	catx	Proceeds From Issuance Of Common Stock And Prefunded Warrants Net ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsNet	0
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	65000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	288412000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	432000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	242766000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7326000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9420000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	252186000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28501000
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	252004000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28319000
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	252186000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28501000
	catx	Recognition Of Operating Lease Liability And Right Of Use Asset RecognitionOfOperatingLeaseLiabilityAndRightOfUseAsset	1497000
	catx	Recognition Of Operating Lease Liability And Right Of Use Asset RecognitionOfOperatingLeaseLiabilityAndRightOfUseAsset	0
	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	0
	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	85885000
	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1	136545072
	us-gaap	Stock Issued1 StockIssued1	0
	us-gaap	Stock Issued1 StockIssued1	54618000
	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	0
	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	-7836000
	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	0
	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	-6171000
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	54642000
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	54553000
CY2023Q1	catx	Adjustments To Additional Paid In Capital Assumption Of Stock Options And Warrants At Fair Value AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue	7836000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1368000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-371000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	118028000
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	532000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1199000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11106000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	108653000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	75179000
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	126000
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	587000
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1050000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1209000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2032000
	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	6
CY2023Q4	catx	Aggregate Maximum Estimate Settlement Amount AggregateMaximumEstimateSettlementAmount	200000
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	300
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	0
	us-gaap	Operating Lease Expense OperatingLeaseExpense	0
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	408000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	949000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	482000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	320000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	283000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2442000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	272000
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2170000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	720000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1450000
CY2024Q2	catx	Estimated Hazardous Waste Removal Liability EstimatedHazardousWasteRemovalLiability	500000
CY2023Q4	catx	Estimated Hazardous Waste Removal Liability EstimatedHazardousWasteRemovalLiability	500000
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	29000
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	52000
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	55000
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1569000
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	1705000
CY2023Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	588000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	905000
CY2023Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-9486000
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-16160000
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	catx	Rule10 B51 Arr Modified Flag Rule10B51ArrModifiedFlag	false
CY2024Q2	catx	Non Rule10 B51 Arrangement Modified Flag NonRule10B51ArrangementModifiedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000950170-24-096148-index-headers.html	Edgar Link	pending
0000950170-24-096148-index.html	Edgar Link	pending
0000950170-24-096148.txt	Edgar Link	pending
0000950170-24-096148-xbrl.zip	Edgar Link	pending
catx-20240630.htm	Edgar Link	pending
catx-20240630.xsd	Edgar Link	pending
catx-ex10_1.htm	Edgar Link	pending
catx-ex10_2.htm	Edgar Link	pending
catx-ex31_1.htm	Edgar Link	pending
catx-ex31_2.htm	Edgar Link	pending
catx-ex31_3.htm	Edgar Link	pending
catx-ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
catx-20240630_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2024 Q3 Form 10-Q Financial Statement

#000095017024096148 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2024 Q3 Form 10-Q Financial Statement

#000095017024096148 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx